KR20230142701A - 중증 급성 호흡기 증후군-관련 코로나바이러스를 표적화하는간섭 rna 및 covid-19 치료를 위한 그의 용도 - Google Patents

중증 급성 호흡기 증후군-관련 코로나바이러스를 표적화하는간섭 rna 및 covid-19 치료를 위한 그의 용도 Download PDF

Info

Publication number
KR20230142701A
KR20230142701A KR1020237022322A KR20237022322A KR20230142701A KR 20230142701 A KR20230142701 A KR 20230142701A KR 1020237022322 A KR1020237022322 A KR 1020237022322A KR 20237022322 A KR20237022322 A KR 20237022322A KR 20230142701 A KR20230142701 A KR 20230142701A
Authority
KR
South Korea
Prior art keywords
seq
sars
cov
sirna
rna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237022322A
Other languages
English (en)
Korean (ko)
Inventor
이충 창
치판 양
이펜 첸
치아춘 양
유안린 초우
Original Assignee
마이크로바이오 (상하이) 컴퍼니 리미티드
원니스 바이오테크 컴퍼니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 마이크로바이오 (상하이) 컴퍼니 리미티드, 원니스 바이오테크 컴퍼니 리미티드 filed Critical 마이크로바이오 (상하이) 컴퍼니 리미티드
Publication of KR20230142701A publication Critical patent/KR20230142701A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3521—Methyl
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
    • C12N2310/3533—Halogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020237022322A 2020-12-03 2021-12-03 중증 급성 호흡기 증후군-관련 코로나바이러스를 표적화하는간섭 rna 및 covid-19 치료를 위한 그의 용도 Pending KR20230142701A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2020133565 2020-12-03
CNPCT/CN2020/133565 2020-12-03
CNPCT/CN2021/121762 2021-09-29
CN2021121762 2021-09-29
PCT/CN2021/135476 WO2022117085A1 (en) 2020-12-03 2021-12-03 Interfering rnas targeting severe acute respiratory syndrome-associated coronavirus and uses thereof for treating covid-19

Publications (1)

Publication Number Publication Date
KR20230142701A true KR20230142701A (ko) 2023-10-11

Family

ID=81853844

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237022322A Pending KR20230142701A (ko) 2020-12-03 2021-12-03 중증 급성 호흡기 증후군-관련 코로나바이러스를 표적화하는간섭 rna 및 covid-19 치료를 위한 그의 용도

Country Status (8)

Country Link
US (1) US20240026362A1 (cg-RX-API-DMAC7.html)
EP (1) EP4256055A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023553610A (cg-RX-API-DMAC7.html)
KR (1) KR20230142701A (cg-RX-API-DMAC7.html)
CN (1) CN116964202A (cg-RX-API-DMAC7.html)
AU (1) AU2021390130A1 (cg-RX-API-DMAC7.html)
IL (1) IL303367A (cg-RX-API-DMAC7.html)
WO (1) WO2022117085A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117919267B (zh) * 2024-01-24 2024-12-03 石河子大学 miR2911在制备抗猪繁殖与呼吸障碍综合症病毒的药物中的应用
CN118001297B (zh) * 2024-02-01 2025-01-28 中国人民解放军军事科学院军事医学研究院 一种治疗SARS-CoV-2及其变体感染的多功能组合物及其制备方法
CN118853668B (zh) * 2024-06-24 2026-07-17 中山大学 一种靶向SARS-CoV-2的siRNA自组装纳米颗粒及其制备方法与应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004221760B2 (en) * 2003-03-21 2010-03-18 Roche Innovation Center Copenhagen A/S Short interfering RNA (siRNA) analogues
CN1590545A (zh) * 2003-06-04 2005-03-09 杭州新瑞佳生物医药技术开发有限公司 攻击SARS病毒mRNA分子的小干扰核糖核酸分子(SiRNA)及应用
CN101113158A (zh) * 2006-12-18 2008-01-30 四川大学 干扰SARS病毒RdRp基因功能的siRNA
US10822379B1 (en) * 2020-03-12 2020-11-03 University of Pittsburgh—of the Commonwealth System of Higher Education Molecules that bind to SARS-CoV-2
US20230174975A1 (en) * 2020-03-13 2023-06-08 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods for viral genome targeting
WO2021195307A1 (en) * 2020-03-26 2021-09-30 Alnylam Pharmaceuticals, Inc. Coronavirus irna compositions and methods of use thereof
CN111849988B (zh) * 2020-04-03 2022-02-18 苏州吉玛基因股份有限公司 一种小干扰核酸及组合物和应用
CN111139241B (zh) * 2020-04-03 2020-09-01 苏州吉玛基因股份有限公司 抑制新型冠状病毒的小干扰核酸及组合物和应用
TW202204619A (zh) * 2020-04-10 2022-02-01 美商艾利格斯醫療公司 短干擾核酸(siNA)分子及其用於冠狀病毒疾病之用途
CN111518809A (zh) * 2020-05-12 2020-08-11 杭州勇诚睿生物科技有限公司 干扰新冠病毒COVID-19基因表达的siRNA及其应用
RU2733361C1 (ru) * 2020-07-14 2020-10-01 Федеральное государственное бюджетное учреждение "Государственный научный центр "Институт иммунологии" Федерального медико-биологического агентства России (ФГБУ "ГНЦ Институт иммунологии" ФМБА России) Средство для ингибирования репликации вируса SARS-CoV-2, опосредованного РНК-интерференцией
WO2022269097A1 (en) * 2021-06-25 2022-12-29 Alpine Antiviral Gmbh Sirna combinations targeting sars-cov-2 and/or host factor transcripts

Also Published As

Publication number Publication date
CN116964202A (zh) 2023-10-27
IL303367A (en) 2023-08-01
WO2022117085A1 (en) 2022-06-09
AU2021390130A1 (en) 2023-06-29
AU2021390130A9 (en) 2025-04-03
EP4256055A4 (en) 2025-07-02
EP4256055A1 (en) 2023-10-11
JP2023553610A (ja) 2023-12-25
US20240026362A1 (en) 2024-01-25

Similar Documents

Publication Publication Date Title
Chang et al. A siRNA targets and inhibits a broad range of SARS‐CoV‐2 infections including Delta variant
WO2022117085A1 (en) Interfering rnas targeting severe acute respiratory syndrome-associated coronavirus and uses thereof for treating covid-19
US11028397B2 (en) 5′-triphosphate oligoribonucleotides
EP3386519B1 (en) Sirna structures for high activity and reduced off target
US20140287023A1 (en) 5'-triphosphate oligoribonucleotides
WO2023098908A1 (en) Modification patterns for small interfering rna molecules with high stability and gene silencing activities
US20140323541A1 (en) Methods And Compositions For Prevention Or Treatment Of RSV Infection Using Modified Duplex RNA Molecules
TW202214296A (zh) 核酸脂質粒子疫苗
WO2021237297A1 (en) Anti-viral extracellular vesicles, their methods of preparation and uses
CN105555279B (zh) 用于治疗脓毒症的MicroRNA抑制
CN114729360A (zh) 降低病毒分子水平的方法
WO2023023597A1 (en) Virus-like particle
CN105899238A (zh) 通过调节微RNAmiR-130a、miR-130b、miR-204或miR-1236治疗肝炎病毒感染
WO2021237067A9 (en) Interferon- inducing oligonucleotide duplexes and methods of use
US20240425853A1 (en) Modified small interfering rna molecules with reduced off-target effects
WO2026067447A1 (en) Small Interfering RNAs Targeting ANT2 and Uses Thereof for Disease Treatment
US20240024405A1 (en) Compositions of caspase inhibitors and methods of use thereof
JP2025534045A (ja) 抗ウイルス核酸および組成物
US20250339502A1 (en) Ribonucleases for treating viral infections
WO2026096962A1 (en) Methods and compounds for treating, ameliorating and/or preventing fibrotic diseases
WO2024206843A9 (en) Compositions including modified coronavirus vaccines and uses thereof
WO2026058828A1 (ja) Rsv lタンパク質 rna配列に基づく新規二本鎖rna及びその利用
WO2025067322A1 (zh) 一种新的siRNA、包含其的组合物及用途
CN118403065A (zh) 用于肿瘤治疗的化疗药物组合物及其制备方法
Kim et al. Duox2-derived reactive oxygen species induce pattern recognition receptors’ expression against influenza A virus in nasal mucosa

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000